Dr Rebecca Lehmann
Conjoint Associate Lecturer

Dr Rebecca Lehmann

Bachelor of Science (BiomedSc), University of Adelaide, 2010-2012

Bachelor of Science (Hons), University of Adelaide, 2013

PhD, University of Adelaide, 2015-2019

 

 

Medicine & Health
School of Clinical Medicine

Dr. Rebecca Lehmann is currently a postdoctoral researcher in the Brain Tumour group at the Children's Cancer Institute, under the supervision of Dr. Ben Rayner and A/Prof David Ziegler. Rebecca graduated from a Bachelor of Biomedical Science in 2013 from the University of Adelaide with First Class Honours, and received her PhD from the University of Adelaide in 2019. During her PhD candidature, Rebecca investigated the mechanisms underlying the severe neurological pathology of the paediatric neurodegenerative disease, Mucopolysaccharidosis, examining the effects of increased heparan sulphate content and aberrant sulphation patterning on stem cell differentiation. In 2019, following completion of her PhD, Rebecca started as a postdoctoral researcher in the Brain Tumour Group at the Children's Cancer Institute. Her work focuses on identifying new treatments for children with the universally lethal brain tumour, Diffuse Midline Glioma, and other hard to treat childhood brain tumours. 

Location
Children's Cancer Institute
  • Journal articles | 2021
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG', Cell Reports, vol. 35, pp. 108994 - 108994, http://dx.doi.org/10.1016/j.celrep.2021.108994
    Journal articles | 2021
    Hayden E; Holliday H; Lehmann R; Khan A; Tsoli M; Rayner BS; Ziegler DS, 2021, 'Therapeutic targets in diffuse midline gliomas—an emerging landscape', Cancers, vol. 13, pp. 6251 - 6251, http://dx.doi.org/10.3390/cancers13246251
    Journal articles | 2021
    Lehmann RJ; Jolly LA; Johnson BV; Lord MS; Kim HN; Saville JT; Fuller M; Byers S; Derrick-Roberts ALK, 2021, 'Impaired neural differentiation of MPS IIIA patient induced pluripotent stem cell-derived neural progenitor cells', Molecular Genetics and Metabolism Reports, vol. 29, http://dx.doi.org/10.1016/j.ymgmr.2021.100811
    Journal articles | 2017
    Saville JT; Hong NT; Lehmann RJ; Derrick-Roberts ALK; Fuller M, 2017, 'Subregional brain distribution of simple and complex glycosphingolipids in the mucopolysaccharidosis type I (Hurler syndrome) mouse: impact of diet', JOURNAL OF NEUROCHEMISTRY, vol. 141, pp. 287 - 295, http://dx.doi.org/10.1111/jnc.13976
    Journal articles | 2016
    Saville JT; Lehmann RJ; Derrick-Roberts ALK; Fuller M, 2016, 'Selective normalisation of regional brain bis(monoacylglycero)phosphate in the mucopolysaccharidosis 1 (Hurler) mouse', EXPERIMENTAL NEUROLOGY, vol. 277, pp. 68 - 75, http://dx.doi.org/10.1016/j.expneurol.2015.12.012
  • Conference Abstracts | 2021
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Hayden E; Rouaen J; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Kankean A; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov A; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS, 2021, 'TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 18 - 19, http://dx.doi.org/10.1093/neuonc/noab090.075
    Conference Abstracts | 2020
    Ehteda A; Franshaw L; Liu J; Joshi S; Simon S; Pang CNI; Giorgi F; Pandher R; Ung C; Tolhurst O; Mayoh C; Khan A; Hayden E; Gopalakrishnan A; Trebilcock P; Upton D; Lehmann R; George S; Vittorio O; Tsoli M; Gurova K; Gudkov AG; Norris MD; Haber M; Ziegler DS, 2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii292, http://dx.doi.org/10.1093/neuonc/noaa222.076
    Conference Papers | 2020
    Ehteda A; Franshaw L; Liu J; Joshi S; Simon S; Pang CNI; Giorgi F; Pandher R; Ung C; Tolhurst O; Mayoh C; Khan A; Hayden E; Gopalakrishnan A; Trebilcock P; Upton D; Lehmann R; George S; Vittorio O; Tsoli M; Gurova K; Gudkov AG; Norris MD; Haber M; Ziegler DS, 2020, 'TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, pp. 292 - 292, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2021    University of Adelaide AMS/Biomedicine Publication Award

2018    Fresh Science Competition South Australian Finalist

2018    Hospital Research Foundation BioMed City Travel Award 

2018    National Stem Cell Foundation of Australia Travel Award

2018    Walter and Dorothy Duncan Trust Travel Grant 

2017    Australian and New Zealand Society for Cell and Developmental Biology (ANZSCDB) Outstanding Student Oral Presentation Prize

2017    Australasian Society of Stem Cell Research (ASSCR) Travel Award

2015    Matrix Biology Society of Australia and New Zealand (MBSANZ) Travel Award

2015    Australian Postgraduate Award (PhD Scholarship)

2013    University of Adelaide Molecular and Biomedical Science Honours Scholarship

1. Determining the efficacy of CDK4/6 inhibitor combination treatments for Diffuse Midline Glioma

2. Identifying new treatments for BRAF/MEK inhibitor resistant paediatric brain tumours

3. Identifying treatments for H3K27M wild type DIPG tumours